STOCK TITAN
  1. Home
  2. Sec-filings
  3. GRTX
  4. [8-K] Galera Therapeutics, Inc. Reports Material Event

Galera Therapeutics (GRTX) plans 1-for-200 reverse stock split in July 2026

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Galera Therapeutics approved a one-for-two hundred reverse stock split of its common stock. Every 200 existing shares will automatically convert into one share at the effective time on July 12, 2026, with split-adjusted trading expected to begin on July 13, 2026.

No fractional shares will be issued; instead, stockholders will receive cash equal to the fractional share amount multiplied by the closing price on the last trading day before effectiveness. The split will proportionally reduce shares available under the 2019 Equity Incentive Plan and 2023 Employment Inducement Award Plan and the shares issuable upon exercise of outstanding stock options and warrants, while increasing their exercise prices proportionately.

Positive

  • None.

Negative

  • None.

Insights

Galera is consolidating its share count via a large 1-for-200 reverse split.

Galera Therapeutics’ board approved a 1-for-200 reverse stock split, meaning every 200 existing common shares will become one new share. This takes effect at 11:59 p.m. Eastern Time on July 12, 2026, with trading on a split-adjusted basis starting July 13, 2026.

Holders will receive cash instead of fractional shares, based on the OTCQB Market closing price on the last trading day before effectiveness. The split also reduces shares available under the 2019 Equity Incentive Plan and 2023 Employment Inducement Award Plan and the number of shares underlying stock options and warrants, with exercise prices adjusted upward proportionately.

This action primarily changes Galera’s capital structure rather than its operations or earnings. The economic ownership percentages for investors remain aligned after the split because both share counts and related derivative instruments are being adjusted on the same 1-for-200 basis.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Reverse split ratio 1-for-200 Every 200 shares convert into 1 share
Effective date and time July 12, 2026, 11:59 p.m. ET Reverse split effectiveness
Split-adjusted trading start July 13, 2026 GRTX trading on OTCQB Market
Common stock par value $0.001 per share Class of common stock affected
reverse stock split financial
"approved a one-for-two hundred (1:200) reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
OTCQB Market market
"as reported on the OTCQB Market, on the last trading day"
The OTCQB Market is a regulated tier of the over‑the‑counter (OTC) trading system where smaller or early‑stage stocks trade with modest reporting and quality standards. Think of it as a neighborhood market that sits between an informal garage sale and a big supermarket: it offers more information and oversight than the lowest OTC tier, but less liquidity and scrutiny than major exchanges. Investors care because it signals a middle level of transparency and risk, affecting how easy shares are to buy, sell and evaluate.
Equity Incentive Plan financial
"available for issuance under the Company’s 2019 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
warrants financial
"shares of Common Stock issuable upon the exercise of the Company’s outstanding warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
exercise price financial
"corresponding increase in the exercise price per share applicable to outstanding stock options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

What reverse stock split did Galera Therapeutics (GRTX) approve?
Galera Therapeutics approved a one-for-two hundred reverse stock split of its common stock. Every 200 existing shares will automatically convert into one share at the effective time, consolidating the share count without changing each investor’s proportional ownership.

When will the Galera Therapeutics (GRTX) reverse split take effect and trade?
The reverse stock split becomes effective on July 12, 2026 at 11:59 p.m. Eastern Time. Galera Therapeutics shares are expected to begin trading on a split-adjusted basis on July 13, 2026 on the OTCQB Market under the GRTX symbol.

How will Galera Therapeutics (GRTX) handle fractional shares in the reverse split?
Galera Therapeutics will not issue fractional shares in the reverse split. Instead, stockholders receive cash equal to their fractional share amount multiplied by the closing GRTX price on the OTCQB Market on the last trading day before the effective date.

How does the Galera Therapeutics (GRTX) reverse split affect stock options and warrants?
The reverse split will proportionally reduce the number of Galera shares issuable upon exercise of outstanding stock options and warrants. At the same time, the exercise price per share of each option and warrant will increase proportionately, maintaining the overall economic value of these instruments.

What happens to Galera Therapeutics’ (GRTX) equity incentive plans after the reverse split?
After the reverse split, the number of shares available for issuance under Galera’s 2019 Equity Incentive Plan and 2023 Employment Inducement Award Plan will be reduced proportionately. This aligns the plans’ share reserves with the new, lower total share count following the 1-for-200 split.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
NONE 0001563577 false 0001563577 2026-07-07 2026-07-07
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 7, 2026

 

 

GALERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39114   46-1454898

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

(Address of principal executive offices) (Zip Code)

(610) 725-1500

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   GRTX   OTCQB Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 8.01

Other Events.

On July 7, 2026, Galera Therapeutics, Inc., a Delaware corporation (the “Company”), announced that its board of directors approved a one-for-two hundred (1:200) reverse stock split (“Reverse Stock Split”) of the Company’s common stock, par value $0.001 (“Common Stock”).

The Reverse Stock Split is expected to become effective on July 12, 2026 as of 11:59 p.m. Eastern Time (the “Effective Time”), with shares to begin trading on a split-adjusted basis at market open on July 13, 2026. In connection with the Reverse Stock Split, every two hundred shares of Common Stock issued and outstanding as of the Effective Time will be automatically converted into one share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split; the Company’s stockholders will be entitled to receive the cash value equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of Common Stock, as reported on the OTCQB Market, on the last trading day prior to the effective date of the Reverse Stock Split.

In addition, the Reverse Stock Split will effect a reduction in the number of shares of Common Stock (i) available for issuance under the Company’s 2019 Equity Incentive Plan and 2023 Employment Inducement Award Plan, and (ii) issuable upon the exercise of stock options outstanding immediately prior to the effectiveness of the Reverse Stock Split. To reflect the Reverse Stock Split, there will also be a corresponding increase in the exercise price per share applicable to outstanding stock options.

The Reverse Stock Split will also effect a proportionate reduction in the number of shares of Common Stock issuable upon the exercise of the Company’s outstanding warrants, with a corresponding adjustment to the exercise price per share applicable to each such warrant.

The aforementioned adjustments will occur automatically upon effectiveness of the Reverse Stock Split.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    GALERA THERAPEUTICS, INC.
Date: July 7, 2026     By:  

/s/ J. Mel Sorensen, M.D.

      J. Mel Sorensen, M.D.
      President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents